2 receptor selectivity and
specificity of the antihypertensive agent moxonidine. Arzneimittelforsch. 38, 1435—1442.
Berridge T. L., Gadie B., Roach A. G., and Tulloch I. F. (1983) a2- Adrenoceptor agonists induce mydriasis in the rat by an action
within the central nervous system. Br. J. Pharmacol. 78, 507—
515.
BondareffW., Mountjoy C. Q., and Roth M. (1982) Loss of neurons
of origin of the adrenergic projection to cerebral cortex (nucleus
locus coeruleus) in senile dementia. Neurology 32, 164— 168.
Bugajski J., Zacny E., and Zdebska A. (1980) The involvement of
central a-adrenergic and histamine H2-receptors in the hypothermia induced by clonidine in the rat. Neuropharmacology
19, 9—15.
Cambridge D. (1981) UK- 14304, a potent and selective a2-agonist
for the characterization of a-adrenoceptor subtypes. Eur. J.
Pharmacol. 72, 413—415.
Chapleo C. B., Doxey J. C., Myers P. L., and Roach A. G. (1981)
RX 781094, a new potent, selective antagonist of a2-adrenoceptors. (Abstr.) Br. J. Pharmacol. 74, 842P.
Colpaert F. C. (1986a) Effects of putative a-adrenoceptor antagonists and of other compounds on the loss of the righting reflex
and on exophthalmia induced by xylazine in the rat. Drug Dev.
Res. 7, 125—140.
Colpaert F. C. (1986b) Maximal magnitude of effect and potency
of putative a-adrenoceptor agonists in causing CNS depression,
in relaxing muscle, and in lowering body temperature in rat.
Drug Dcv. Res. 7, 209—220.
Colpaert F. C. (1994) Noradrenergic mechanisms in Parkinson's
disease: a theory, in Noradrenergic Mechanisms in Parkinson's
Disease (Briley M. and Marien M., eds), pp. 225—254. CRC
Press, Boca Raton, Florida.
Colpaert F. C. and Janssen P. A. J. (1986) Discriminative stimulus
properties of xylazine in rat: discriminability and effects of
putative a2 adrenoceptor agonists and antagonists. J. Pharmacol. Exp. Ther. 235, 521—527.
Coull J. T., Sahakian B. J., and Hodges J. R. (1996) Thea2 antago- a
